ClinicalTrials.gg

Thyroid Neoplasms clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 785 studies for Thyroid Neoplasms across more than 10 countries. 204 are recruiting or about to start. 502 of them are mainly about Thyroid Neoplasms (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-16. Counting its 3 narrower conditions too, such as Thyroid Nodule: 1,039 studies, 289 open.

ClinicalTrials.gov finds 1,288 studies for Thyroid Neoplasms. How that becomes 785 here

This page counts the studies the registry files under Thyroid Neoplasms, and those it files under no condition that list Thyroid Neoplasmsthemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 8, 2026. How condition pages count

  1. 1,288Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −223Filed under a narrower condition, counted on its own pageThyroid Nodule 117 · Thyroid Cancer, Papillary 101 · Papillary Thyroid Microcarcinoma 2
  3. −118List Thyroid Neoplasms as a condition, but the registry did not file them under itMost often written as “Medullary Thyroid Cancer” (29), “Medullary Thyroid Carcinoma” (23), and “Anaplastic Thyroid Cancer” (20). The registry filed them under other conditions only, most often Carcinoma, Medullary (62) and Thyroid Carcinoma, Anaplastic (31).
  4. −162Match it another way50 name it in the title, 10 in a keyword, and 102 by a synonym or other text the search reads.
  5. 785The count on this page63 of them list Thyroid Neoplasms in their own words; the registry filed them under no condition.

Status

Completed
333
Recruiting
152
Status unknown
112
Active, not recruiting
67
Terminated
48
Not yet recruiting
45

Phase

Phase 2
217
Phase 1
98
Phase 3
42
Phase 4
22
Early Phase 1
6

Where

United States
283
China
160
France
72
Korea, Republic of
59
Italy
58
Canada
38

Who develops what

Add Thyroid Neoplasms to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 8 programs from 7 companies, 4 with this as their studies’ main aim; 1 with a live phase 3 study; 3 primary completions in the next 12 months. Compare Rigel Pharmaceuticals, Eli Lilly and Sino Biopharmaceutical here →

Stage, biomarker and line of therapy are not read yet: these programs are in development here, not all in the same competitive position.

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
pembrolizumabRecent, limited
Evidence
  • NCT05620134 · Shenzhen Salubris Pharmaceuticals Co., Ltd. · Phase 2 · live · background · “Pembrolizumab” · registered Nov 2022
Merck & Co., Inc74% of its industry studiesUS: Merck & Co., Inc (FDA 2014)EU: Merck & Co., Inc (EMA 2015)11 study
trametinibRecent, limited
Evidence
  • NCT05275374 · Xynomic Pharmaceuticals, Inc. · Phase 2 · live · background · “Trametinib” · registered Feb 2022
GlaxoSmithKline49% of its industry studiesEU: Novartis (EMA 2014)11 study
lenvatinibRecent, limited
Evidence
  • NCT05620134 · Shenzhen Salubris Pharmaceuticals Co., Ltd. · Phase 2 · live · background · “Lenvatinib Pill” · registered Nov 2022
Eisai Co., Ltd.63% of its industry studiesUS: Eisai Co., Ltd. (FDA 2015)EU: Eisai Co., Ltd. (EMA 2015)11 study

2 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
vilzemetkib☆ Track1 live phase-3 study: NCT06860971Sino Biopharmaceutical Limited

The 1 in phase 3 with the nearest primary completion, of 8 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (3)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • 30 Nov 2026 est.KRAS G12D Degrader ARV-806 · Arvinas Inc. · Phase 2 registry mapping onlyNCT07023731 A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation — primary endpoint: Part A (Phase 1): Number of dose-limiting toxicities (DLTs) of ARV-806 · 76 enrolled
  • Jan 2027 est.vilzemetkib · Sino Biopharmaceutical Limited · Phase 3 main aimNCT06860971 A Study of AL2846 Capsule Versus Placebo in the Treatment of Advanced Radioiodine-Refractory Differentiated Thyroid Carcinoma — primary endpoint: Progression - Free Survival (PFS) evaluated by the Independent Review Committee (IRC) · 144 enrolled
  • 30 Jul 2027 est.pralsetinib, CYP3A4, CYP2C8, and CYP2C9 substrates, and hormonal contraceptive · Rigel Pharmaceuticals · Phase 4 named, not the main aimNCT07704658 Pralsetinib DDI Study in Patients With Advanced or Metastatic Solid Tumors — primary endpoint: Area Under the Plasma Concentration-Time Curve from zero to infinity (AUC0-inf) · 12 enrolled

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Thyroid Neoplasms studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Tyrosine kinase inhibitors (TKIs) 16 open · Immune checkpoint inhibitors 5 open · Alkylating agents 2 open · Angiogenesis inhibitors 1 open · Antimitotic agents 1 open

Coming up

66studies finish main data collection within a year2 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 152 Thyroid Neoplasms studies recruiting now, 96 (63%) set no upper age limit and 27 (18%) stop at 75 or younger. 37 (24%) take children under 18. 1 (1%) are for women only and 0 (0%) for men only; 13 (9%) take healthy volunteers.

Recruiting studies that take each age, of 152
AgeWomenMen
1027 (18%)27 (18%)
18145 (95%)144 (95%)
30149 (98%)148 (97%)
40150 (99%)149 (98%)
50147 (97%)147 (97%)
65145 (95%)145 (95%)
75138 (91%)138 (91%)
85114 (75%)114 (75%)

Across all 785 studies, recruiting or not: 18% stop at 75 or younger and 9% at 65; 17% take children; 2% are for women only and 1% for men only; 8% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Thyroid Neoplasms studies take

Of 93 phase 2 interventional studies under Thyroid Neoplasms, half reached primary completion within 73 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 157 mo25–81 · 38 studies——
Phase 1/236 mo28–81 · 21 studies——
Phase 273 mo39–119 · 93 studies—84 mo50–124 · 78 studies
Phase 338 mo30–106 · 19 studies——
Interventional, no phase46 mo14–78 · 127 studies—46 mo14–78 · 126 studies
Observational63 mo26–311 · 112 studies—71 mo24–311 · 103 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 785. Browse all 785 → or search them.